JPRN-jRCTs051180030已完成未知
Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitus - CANONICAL study
Saito Yoshihiko0 个研究点目标入组 91 人开始时间: 2019年1月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 91
研究概览
简要总结
In this study, 82cases were the maximum analyzed cases (canagliflozin group [Group A: 42 cases], and standard therapy group [Group B: 40 cases]). There were no significant differences in clinical characteristics between the two groups. In the primary endpoints, body weights were significantly decreased after 24 weeks compared with the baseline values in group A alone, whereas there were no significant changes in BNP of both groups. The incidence of adverse events was similar in the two groups.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 65age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients providing written informed and consent to participate in the study
- •2. Aged >= 65 years (irrespective of sex)
- •3. HbA1c >= 6.5%, and HbA1c <10.0% within 8 weeks. HbA1c >= 7.0% in case of administration of sulfonylurea, and/or glinide
- •4. History of heart failure before consent, and echocardiographic mean E/e' >14 (septal E/e' >15, or lateral E/e' >13 ) , or septal e' <7 cm/min, or lateral e' <10 sec/min and LV ejection fraction >= 50%, with or without atrial fibrillation (AF)
- •5. Plasma BNP >= 100 pg/mL or plasma NT-proBNP >= 400 pg/mL before consent, or plasma BNP >= 40 pg/mL or plasma NT-proBNP >= 125 pg/mL within 8 weeks before consent, with or without atrial fibrillation (AF)
- •6. NYHA cardiac function classification of II-III within 8 weeks prior to the date of informed consent
- •7. Patients who have not changed the dosage and administration of antidiabetic drugs and heart failure drugs from at least 8 weeks before the date of informed consent
排除标准
- •1. Type 1 diabetes
- •2. Patients treated with a glucagon-like peptide-1 (GLP-1) receptor agonists
- •3. Need insulin therapy for blood glucose management (e.g., patients with severe ketosis, diabetic coma or pre-coma, severe infection, perioperative, severe trauma)
- •4. Severe renal dysfunction or chronic renal failure during dialysis (In case of moderate renal dysfunction, patients are carefully judged the need for administration of canagliflozin)
- •5. History of acute coronary syndrome, cerebrovascular disease, myocarditis, contractile pericarditis, or severe valvular disease within 12 weeks before consent,
- •6. NYHA cardiac function classification of IV
- •7. BMI <18.5 kg/m2
- •8. Pregnant, breast-feeding, or possibly pregnant women
- •9. Diagnosed or suspected malignant tumors (Patients who did not treat anti-cancer treatment within 1 year before consent can be entered.)
- •10. Patients who were judged by the investigator to be inappropriate for the study.
研究者
相似试验
已完成
不适用
Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitusHeart failure with preserved ejection fraction in type 2 diabetes mellitusJPRN-UMIN000028668ara Medical Univercity80
终止
2 期
EMPA Acute Heart FailureAcute Heart FailureDiabetes Mellitus, Type 2NCT03554200RWTH Aachen University19
已完成
1 期
A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)HealthyNCT01787357Johnson & Johnson Pharmaceutical Research & Development, L.L.C.60
已完成
不适用
Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection FractionHeart FailureNCT00774709French Cardiology Society90
已完成
4 期
Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02220920Tanabe Pharma Corporation146